Exclusive | Dad says autism miracle drug drastically and immediately improved his sons severe symptoms
Like most four-and-a-half-year-olds, Lev Bielski loves playing with his big sister, spelling his favorite pastime “pool” on the letter board, and cuddling with his parents on movie nights. But it’s been a long journey for the golden-haired “surfer bro” who loves splashing in the water at surf camp and trying on Dad’s volunteer firefighter gear.Up until four months ago, Lev was self-harming until he was black and blue, unable to make eye contact and keeping to himself in a corner all day.He was inching dangerously close to being confined by a punishing helmet and sedated with heavy antipsychotic meds to mitigate his severe autism that left him incapable of functioning by himself.The outlook was bleak for the tormented tyke, who showed symptoms before he was a year old.His parents, Gabriella and Matthew Bielski, chased every therapeutic intervention and specialist across the country for years, to no avail.
The family desperately needed a lifeline, as no medication is approved to address the core symptoms related to autism. “Half my day was running a business and half was holding him down and trying to keep him from hurting himself — we had no solution,” Matthew Bielski told The Post. That was until research led the anguished couple to Yamo Pharmaceuticals, a decade-old clinical-stage biopharmaceutical company dedicated to treating the core symptoms of autism spectrum disorder with its “miracle drug” called L1-79.They managed to get Lev the therapy before FDA approval thanks to the FDA’s expanded-access program — and the results, they said, were immediate.“It was the next day,” Bielski said.“It was right away and other people in all the phases said the same thing.”“It changed everything for us,” he added, beaming over Lev’s “life-changing transformation.”Overjoyed over his “miracle kid,” Bielski predicted the drug will be the “Ozempic of autism.”What separates this investigational oral therapy from other treatmen...